Hints and tips:
Related Special Reports
...The ruling came after Escobar Inc, the company set up by his brother, filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) for registration of the word sign Pablo Escobar...
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...The company has genetically validated two other drug targets....
...The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for...
...insurers to cover the drug....
...Drugs companies issued 1,643 warnings of impending shortages in 2023, compared to 648 in 2020, the research found....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...A top EU court has ruled that the name of the dead Colombian drug kingpin Pablo Escobar cannot be registered as a trademark in the EU....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...The debate over the role of obesity drugs has not yet been settled. In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research....
...Bobby Gaspar, co-founder and chief executive of Orchard, said Lenmeldy was “a paradigm-shifting medicine”, adding that the company was “committed to enabling broad, expedient and sustainable access to this...
...Patients with terminal breast cancer in England will miss out on a new drug already approved in Scotland, after spending watchdog NICE said Enhertu, developed by Japanese pharma company Daiichi Sankyo and...
...“NHS England expected drug companies AstraZeneca and Daiichi Sankyo to offer this treatment at a price that would enable Nice to recommend its use,” NHS England said....
...Instead, drugs companies will be on the hook for an uncapped 20 per cent share of catastrophic costs....
...Chief executive Lars Fruergaard Jørgensen told the Financial Times this month that it was assessing deals for biotech companies with mid-stage drugs....
...Sales of cancer drugs helped AstraZeneca to beat City expectations in 2023, as the FTSE 100 company forecast continued double-digit sales growth in 2024....
...But according to Holst, who has worked as a consultant for the company, it has struggled to develop small-molecule GLP-1 drugs, which are much easier and cheaper for manufacturers to produce at scale....
...company....
...The company plans to “move forward as quickly as possible” with further trials in MASH for the drug....
...drug-related offences in the past two years....
...With new production facilities typically taking several years to come online, companies are leaning heavily on contract manufacturers....
International Edition